Carbidopa
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Carbidopa?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of administered levodopa to cross the blood–brain barrier for central nervous system effect, instead of being peripherally metabolised into substances unable to cross said barrier.
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Lodosyn |
AHFS/Drugs.com | Monograph |
License data | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 76% |
Metabolism | 7 metabolites known, not metabolized extensively |
Elimination half-life | 2 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.778 |
Chemical and physical data | |
Formula | C10H14N2O4 |
Molar mass | 226.232 g·mol−1 |
3D model (JSmol) | |
Melting point | 203 to 205 °C (397 to 401 °F) |
| |
| |
NY (what is this?) (verify) |
Close